Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Gb Sciences Inc (OP: GBLX )

0.0065 -0.0003 (-4.41%)
Streaming Delayed Price Updated: 1:44 PM EDT, Apr 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Gb Sciences Inc

< Previous 1 2 Next >
Gb Sciences’ Novel Parkinson’s Disease Medication is Featured on Worldwide Business with kathy ireland(R)
Via ACCESSWIRE
Gb Sciences' First-in-Class Parkinson's Disease Therapy Successfully Completes Dose Response Study at the University of Lethbridge
Via ACCESSWIRE
GB Sciences' First International Patent Protecting Its Proprietary Cannabinoid-Based Formulations for Parkinson's Disease Has Been Issued in China
Via ACCESSWIRE
Successful 2022 Milestones Support Value of Gb Sciences' AI-Enabled Drug Discovery Platform
Via ACCESSWIRE
Gb Sciences Identifies Novel Cannabis-Inspired Mixtures as Anti-Inflammatory Therapies Based on Proprietary AI-Enabled Drug Discovery Platform
Gb Sciences' innovative approach harnesses the power of plant-based treatments as simplified mixtures that target dangerous hyperinflammatory responses to viral infections. 
Via Newswire.com
Topics Death
Exposures COVID-19 Death
Marijuana And Chronic Pain: Gb Sciences' Nanoparticle Technology Boosts Efficacy Of Cannabis Terpenes
Gb Sciences, Inc. 
Via Benzinga
Not So Fast With The Cannabis-COVID Treatment: Gb Sciences And Michigan State U Researchers Clarify
Following the promising study on cannabinoids and COVID-19 published by Oregon State University, Gb Sciences, Inc. 
Via Benzinga
Gb Sciences Identifies Novel Cannabis-Inspired Mixtures as Anti-Inflammatory Therapies Based on Proprietary AI-Enabled Drug Discovery Platform
Gb Sciences' innovative approach harnesses the power of plant-based treatments as simplified mixtures that target dangerous hyperinflammatory responses to viral infections. 
From Gb Sciences
Via GlobeNewswire
Gb Sciences Addresses Growing Need for Anxiety and Depression Medications With Non-Psychedelic, Kava-Based Formulations
As mental health disorders increasingly impact global populations, Gb Sciences is developing psychotropic but non-psychedelic treatments for anxiety and depression that compete with the emerging... 
Via Newswire.com
Gb Sciences Addresses Growing Need for Anxiety and Depression Medications With Non-Psychedelic, Kava-Based Formulations
As mental health disorders increasingly impact global populations, Gb Sciences is developing psychotropic but non-psychedelic treatments for anxiety and depression that compete with the emerging... 
From Gb Sciences
Via GlobeNewswire
Cannabis Terpenes Reduce Inflammation, Says Gb Sciences Study
Gb Sciences, Inc. (OTCQB: GBLX), a leading plant-inspired, biopharmaceutical research and drug development company, co-published a study that demonstrates the potential of selected cannabinoids and... 
Via Benzinga
Gb Sciences Co-Publishes Study Demonstrating Anti-Inflammatory Properties of Cannabis Ingredients
As published in the journal Food and Chemical Toxicology, the biopharmaceutical drug development firm's sponsored research used co-cultured human, primary immune cells as a model to evaluate the... 
Via Newswire.com
Topics Cannabis
Exposures Cannabis
Gb Sciences' Plant-based Formulations Designed to Treat Anxiety Achieve Statistical Significance in Animal Study
Gb Sciences' anxiety formulations were previously identified using the company's AI-driven PhAROS™ platform, and they have now been evaluated using preclinical zebrafish models of stress at the... 
Via Newswire.com
TODAY: Gb Sciences' President Demonstrates Effectiveness of Simplified Therapeutic Mixtures Inspired by Cannabis Plant Extracts at Canna Pharma 2022 Conference
Dr. Andrea Small-Howard discusses the company's novel process for developing disease-specific, cannabinoid-based therapeutics. 
Via Newswire.com
Topics Cannabis
Exposures Cannabis
New Study Shows Promising Results In Treatment Of Parkinson's Disease With Cannabinoids
Biopharmaceutical research and drug development company, Gb Sciences, Inc. (OTCQB: GBLX), co-published a study in the journal Frontiers in Pharmacology that demonstrates the efficacy of its proprietary... 
Via Benzinga
Gb Sciences Co-Publishes Study Demonstrating Efficacy of Its Proprietary Cannabinoid Mixtures for the Treatment of Parkinson's Disease
As published in Frontiers in Pharmacology, the biopharmaceutical drug development firm's sponsored research has identified and validated cannabinoid ratio-controlled, Minimum Essential Mixtures (MEM)... 
Via Newswire.com
Topics Cannabis
Exposures Cannabis
TODAY: Gb Sciences Describes Drug Development Progress in Pharma's Almanac Journal Article
Gb Sciences is focusing considerable resources on bringing its lead Parkinson's disease formulations to the clinic with promising results; plus, new data validating the efficacy of their novel anxiety... 
Via Newswire.com
Topics Cannabis
Exposures Cannabis
TODAY: Gb Sciences' President and Chief Science Officer Presents Keynote Address on Cannabinoid-Containing Formulations for Parkinson's Disease at 2022 NeuroForum Summit
Dr. Andrea Small-Howard explains that Gb Sciences' multicomponent Parkinson's disease therapeutic addresses this multi-factorial neurodegenerative condition using a combination of cannabinoids that are... 
Via Newswire.com
Topics Intellectual Property
Exposures Intellectual Property Product Safety
TODAY: Gb Sciences Showcases Its PhAROS™ Drug Discovery Platform at the 2nd ALCOR Drug Discovery Platform Summit
President and Chief Science Officer Dr. Andrea Small-Howard demonstrates the platform's utility for predicting novel plant-inspired drug candidates and describes its role in Gb Sciences' future... 
Via Newswire.com
Topics Intellectual Property
Exposures Intellectual Property
TODAY: Gb Sciences' Novel Plant-Inspired Pain Medications Featured at SMi's 22nd Annual Pain Therapeutics Conference
President and Chief Science Officer Dr. Andrea Small-Howard stressed the importance of developing their innovative, plant-inspired formulations as a potentially safer alternative to existing... 
Via Newswire.com
FHI Clinical to Write Clinical Trial Protocol for Development of Gb Sciences' COVID-19-Related, Anti-Inflammatory Therapies
Plant-inspired biopharmaceutical company signs leading contract research organization to help with a go-to-market strategy for its cannabinoid-containing therapy for COVID-related cytokine release... 
Via Newswire.com
Exposures COVID-19
Gb Sciences To Begin Dosage Study For Cannabinoid-Containing Drug For Treatment Of Parkinson's Disease
Gb Sciences, Inc. (OTCQB: GBLX) has selected the University of Lethbridge in Canada to complete a dose range study of Gb Sciences' patent-protected formulations in a rodent model of Parkinson's... 
Via Benzinga
Gb Sciences to Begin Dosage Study for Its Novel Parkinson's Disease Formulations at the University of Lethbridge
Biopharmaceutical research company's plant-inspired formulations entering final stages before first-in-human clinical trials 
Via Newswire.com
Topics Intellectual Property
Exposures Intellectual Property
Gb Sciences' Nanoparticle Encapsulation Technology Improves the Efficacy of Terpenes for Use in Our Chronic Pain Formulations as Demonstrated in New Research Article
On March 25, the University of Seville, Chaminade University, and Gb Sciences co-published the results from Gb Sciences-sponsored study in the International Journal of Pharmaceutics. Gb Sciences'... 
Via Newswire.com
UPDATE: Gb Sciences Issues Shareholder Letter
Biopharmaceutical research company specializing in cannabis- and plant-inspired medicines shares strategic plan for 2022 and key developments from 2021 
Via Newswire.com
Gb Sciences Issues Summary Shareholder Letter
Biopharmaceutical research company specializing in cannabis- and plant-inspired medicines shares strategic plan for 2022 and key developments from 2021 
Via Newswire.com
Gb Sciences Issues Shareholder Letter
Biopharmaceutical research company specializing in cannabis- and plant-inspired medicines shares strategic plan for 2022 and key developments from 2021 
Via Newswire.com
Gb Sciences Granted U.S. Patent for Cannabinoid-Containing Treatment for Advanced Heart Disease, TRPV1-Receptor-Associated Hearing Loss and Urinary Cystitis
This new patent covers receptor-targeted formulations for the treatment of cardiac hypertrophy, TRPV1-receptor-associated hearing loss and urinary cystitis. 
Via Newswire.com
Topics Intellectual Property
Exposures Intellectual Property
Gb Sciences and Michigan State University Researchers Have Identified the Complicated Truth Behind the Opportunity for an Effective Cannabinoid-Based Coronavirus Treatment
Gb Sciences' collaboration with MSU has received media coverage across the country, starting with an interview from WLNS-TV in Lansing, Michigan, and interviews with Gb Sciences in the magazines... 
Via Newswire.com
Topics Cannabis
Exposures COVID-19 Cannabis
The Week In Cannabis: Tilray Earnings And Reactions, Weed And Covid, Italy, Marijuana At The Airport And More
Below is a recap of the main news related to the cannabis industry and markets for the week of January 10, 2022. 
Via Benzinga
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.